Shares of Idexx Laboratories Inc. (NASDAQ:IDXX) hit a new 52-week high during trading on Tuesday . The stock traded as high as $111.14 and last traded at $111.10, with a volume of 208,128 shares traded. The stock had previously closed at $108.62.

Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Idexx Laboratories from a “hold” rating to a “buy” rating and set a $121.00 price objective for the company in a research report on Thursday, August 4th. Northcoast Research upgraded Idexx Laboratories from a “sell” rating to a “neutral” rating in a report on Wednesday, August 3rd. Stifel Nicolaus reiterated a “buy” rating and issued a $120.00 target price (up from $92.00) on shares of Idexx Laboratories in a report on Wednesday, August 3rd. Canaccord Genuity increased their target price on Idexx Laboratories from $90.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 20th. Finally, TheStreet upgraded Idexx Laboratories from a “hold” rating to a “buy” rating in a report on Friday, April 29th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $99.80.

The company has a market cap of $9.84 billion and a price-to-earnings ratio of 49.81. The firm’s 50-day moving average is $95.97 and its 200 day moving average is $83.88.

Idexx Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 2nd. The company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.12. During the same period last year, the firm posted $0.60 earnings per share. The business had revenue of $467 million for the quarter, compared to analysts’ expectations of $444.83 million. Idexx Laboratories’s quarterly revenue was up 12.9% on a year-over-year basis. On average, equities analysts anticipate that Idexx Laboratories Inc. will post $2.36 earnings per share for the current year.

In related news, Chairman Jonathan W. Ayers sold 60,000 shares of the company’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $107.69, for a total value of $6,461,400.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director William T. End sold 5,000 shares of the company’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $108.50, for a total value of $542,500.00. Following the completion of the sale, the director now directly owns 53,564 shares in the company, valued at $5,811,694. The disclosure for this sale can be found here.

A number of large investors have recently modified their holdings of the company. Morgan Stanley boosted its stake in shares of Idexx Laboratories by 41.3% in the fourth quarter. Morgan Stanley now owns 272,672 shares of the company’s stock valued at $19,883,000 after buying an additional 79,704 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Idexx Laboratories by 1.8% in the fourth quarter. Principal Financial Group Inc. now owns 296,034 shares of the company’s stock valued at $21,587,000 after buying an additional 5,318 shares during the last quarter. Advisors Asset Management Inc. boosted its stake in shares of Idexx Laboratories by 2.9% in the fourth quarter. Advisors Asset Management Inc. now owns 17,027 shares of the company’s stock valued at $1,242,000 after buying an additional 487 shares during the last quarter. Finally, US Bancorp DE boosted its stake in shares of Idexx Laboratories by 7.2% in the fourth quarter. US Bancorp DE now owns 39,115 shares of the company’s stock valued at $2,853,000 after buying an additional 2,612 shares during the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.